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ABSTRACT
Statement of Purpose, Innovation or Hypothesis: Space Motion sickness (SMS) is 
a long-standing problem for astronauts on both short and long duration space flights. 
Scopolamine (SCOP) is frequently used for the treatment of motion sickness (MS), 
and is available as transdermal patch and tablet dosage forms. These formulations of 
SCOP are ineffective for the treatment of SMS. Intranasal dosage forms are 
noninvasive with rapid absorption and enhanced bioavailability, thus allowing precise 
and reduced dosing in addition to offering rescue and treatment options.  An 
intranasal gel dosage formulation of scopolamine (INSCOP) was developed and 
pharmacokinetics (PK) and bioavailability were determined in clinical trials with human 
subjects under IND guidelines.
Description of Methods and Materials : The present clinical trial compares PK and 
bioavailability of INSCOP in 12 normal, healthy subjects (6 male/ 6 female) during 
ambulation (AMB) and antiorthostatic bed rest (ABR) used as a ground-based 
microgravity analog. Subjects received 0.2 mg and 0.4 mg doses of INSCOP during 
AMB and ABR in a 4-way crossover design.
Data and Results : Results indicated no difference between AMB and ABR in PK 
parameters after 0.2 mg dose, Clearance (Cls) decreased with a concomitant 
increase in maximum concentration and area under concentration-versus-time curve 
(AUC) during ABR after the 0.4 mg dose.
Interpretation, Conclusion or Significance : The difference in AUC and Cls at the 
higher (0.4 mg) but not the lower dose (0.2 mg) during ABR suggests that ABR may 
affect metabolism and/or clearance of INSCOP at higher doses . These results 
indicate that dosing adjustment may be required for treatment of SMS with INSCOP in 
space.
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Table 1. Pharmacokinetic parameters of INSCOP after administration to human subjects 
Figure 1. Mean plasma concentration time profiles of scopolamine after 0.2 and
0.4mg intranasal dosing during ambulatory and antiorthostatic bed rest
conditions
After intranasal administration of scopolamine to human subjects during AMB and 
ABR conditions PK parameters were similar at the low dose (0.2 mg), but not at the 
high dose (0.4 mg) between the two conditions. Comparison of Cmax and AUC 
values suggest that treatments between the two conditions were not bioequivalent 
when the 90% confidence intervals fell outside the specified limits of  80 and 125% 
for both doses tested.
Dose Parameters Ambulatory Antiorthostatic Bed Rest
Mean SD Mean SD
0.2 mg T1/2 (hr) 3.23 1.95 2.80 1.15
Tmax (hr) 1.27 0.78 0.83 0.20
Cmax (hr) 409.53 234.43 464.83 208.10
AUClast (hr.pg/mL) 1364.85 969.56 1435.46 786.72
Cl/F (L/hr) 163.78 74.4 152.87 69.97
Vz/F(L) 706.02 504.34 531.56 167.77
AUCINF (hr.pg/mL) 1562.28 1077.64 1621.17 893.65
0.4 mg T1/2 (hr) 3.14 4.36 5.02 4.89
Tmax (hr) 1.04 0.64 0.96 0.38
Cmax (hr) 810.66 329.20 897.88 398.44
AUClast (hr.pg/mL) 2642.24 1490.97 3106.12 2101.43
Cl/F (L/hr) 167.79 59.11 144.83 61.17
Vz/F(L) 526.63 198.51 826.47 724.75
AUCINF (hr.pg/mL) 2929.00** 2012.18 3534.07** 2462.53
INTRODUCTION
Motion sickness (MS) is a long-standing problem for space travelers on short and 
long duration space flight. Oral antiemetics are not very effective in space due to poor 
bioavailability.
Scopolamine (SCOP) is the most frequently used drug by recreational travelers, with 
patches and tablets currently available on the market. Common side effects of 
antiemetics, in general, include drowsiness, sedation, dry mouth and reduced 
psychomotor performance. Severity and persistence of side effects are often dose 
related. Side effects can be detrimental in high-performance demanding settings, 
such as space flight, military.
Oral, injectable and transdermal formulations of SCOP are either invasive, unsuitable 
or ineffective for the treatment of space motion sickness. The intranasal dosage form 
of scopolamine offers great promise for the treatment of MS on Earth and in space:
 It is noninvasive
 Rapid absorption facilitates rescue and treatment options with the same 
formulation
 Enhanced  and reliable bioavailability allows precise and reduced dosing 
options
The plasma concentration time profiles were analyzed using the non-compartmental 
method. After administration of the 0.2mg dose of INSCOP during AMB and ABR, 
AUC values were similar with no significant difference at 95% CI. However, AUC 
values were significantly different after 0.4mg dose. All relevant PK parameter 
estimates are listed in Table 1. 
The parameters were evaluated for bioequivalence between AMB and ABR. Results 
of this evaluation (table 2) showed that the two doses are not bioequivalent with 
ratios at 90% CI, and are outside the specified limits of 80 and 125%.
** P<0.05
Data Analysis
Pharmacokinetic parameters were calculated from the plasma concentration-time 
data by non-compartmental methods using WinNonLin standard edition, version 
5.2. The peak plasma concentration (Cmax) and time to peak concentration (Tmax) 
were determined directly from the plasma profiles. The elimination rate constant 
(Kel) was calculated from the slope of the terminal phase of the plasma 
concentration-time plot. The area under the curve (AUC0-∞) was estimated by the 
linear trapezoidal method with extrapolation to infinity based on the concentration 
of the last time point measured divided by the terminal rate constant. 
Bioequivalence of the two doses between control and ABR was determined at 90%
CI using mean Cmax, AUC(0-t) and AUC(0-∞) with limits between 80.00% and
125.00%.
Study design
The study was randomized and crossover, with subjects (n=12) receiving the 
intranasal formulation under antiorthostatic bed rest conditions or ambulatory 
conditions, at doses 0.2 and 0.4mg. Plasma samples were collected at time points, 
once pre-dose and at 0.17, 0.33, 0.50, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours
post -dose. 
Dose Parameters Ratio Lower CI Upper CI Power
0.2 mg Cmax 121.98 86.05 172.93 0.2760
AUC0-t 111.87 76.31 164.01 0.2471
AUC0-inf 106.63 75.19 151.20 0.2757
0.4 mg Cmax 110.14 84.09 144.27 0.3869
AUC0-t 112.72 80.89 157.09 0.2941
AUC0-inf 118.52 84.05 167.11 0.2815
Table 2 Bioequivalence of INSCOP between AMB and ABR conditions (CI Limits 80-125%)
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